[Video] Rewarding innovation for oncology therapeutics: Can a win-win be achieved?
By NextLevel Life Sciences - February 19, 2016

Leading up to NextLevel Pharma’s PharmAccess Leaders Forum Spring 2016, we would like to share with you a presentation from the 2015 event to give you an sight into the topics the 2016 event will build upon:

Janice Haigh, Practice Leader, Market Access at Quintiles on:
“Rewarding innovation for oncology therapeutics: Can a win-win be achieved?”

Register now & join market access leaders in London at the PharmAccess Leaders Forum Spring 2016!Our Achieving Market Access for High-Value Oncology Therapies stream will focus on the controversial but essential area of patient access for “expensive” cancer medications or companion diagnostics. Payers are searching for true innovation that is affordable, whilst the science often seems to be delivering only incremental benefits to patients or “me too” products for the same indications. Justifying funding decisions for these cancer therapies through sound evidence generation, realistic value-demonstration and stakeholder engagement will be discussed in detail during this mini-event from all sides of the table.


JANICE HAIGH, Practice Leader, Market Access Europe, Quintiles, UK

Janice is Practice Leader for Market Access, Europe within the Consulting division at Quintiles. In this role she is responsible for leading a team of consultants who undertake payer and pricing research, health economics analysis and value development for clients. Before joining Quintiles, Janice was the Head of Pricing and Market Access for Astellas Pharma Europe where she was responsible for developing and implementing pricing and market access strategy for new and in-market products, working closely with brand teams and affiliates. Janice has almost 25 years’ experience in healthcare across Europe and is a Fellow of the Chartered Institute of Marketing. She holds an MSc in Management Science from Imperial College and a BSc in Mathematics from Royal Holloway College, University of London.

For more information regarding NextLevel Pharma’s Achieving Market Access for High-Value Oncology Therapies click here.